Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

March 10, 2020 by Alan Khadavi

Ruxolitinib for Eczema (atopic dermatitis)

Ruxolitinib is a new medication being studied for the treat of eczema.  Ruxolitinib is a selective inhibitor of Janus kinase 1 and Janus kinase 2, it potently suppresses cytokine signaling involved in atopic dermatitis pathogenesis.

We discussed the Janus Kinase pathway in a previous post and how new drugs are being developed for the treatment of eczema for it.

Delgocitinib for patients with atopic dermatitis

Atopic dermatitis is a common inflammatory skin disorder with an estimated cost of 5.3 billion annually in the U.S.  It affects sleep and reduces quality of life. Current treatments remain limited in scope and efficacy.

Treatment of Atopic Dermatitis (Eczema)

New treatments for eczema on the horizon

Eczema is predominantly associated with type 2 immune responses characterized by the elevated production of IL-4,5,13 and 31.  Other drugs in the pipeline are tralokinumab and lebrikizumab.

This is in addition to dupilumab which allergists have been using for sometime now with great success. Janus Kinase inhibitors such as ruxolitinib, inhibit the pathways to directly target diverse pathogenic pathways that underlie atopic dermatitis.  A recent study published in JACI report a controlled phase 2b study comparing different concentrations and regimens of the JAK inhibitor ruxolitinib compared to triamcinolone cream which is a well accepted standard topical steroid. The target population were those who have mild to moderate forms of atopic dermatitis.  The key findings were:

  1. Compared with placebo and triamcinolone, topical ruxolitinib induces a rapid improvement of itching.
  2. Ruxolitinib displays a positive risk benefit ratio.
  3. 1.5% ruxolitinib cream is clearly more efficacious than placebo and seems to be superior the the triamcinolone cream in overall efficacy.
  4. The response to ruxolitinib suggests that the therapeutic effects seems to further improve after the 4 week time endpoint.

Another interesting characteristic of JAK inhibition is the fast mode of action with regard to itching.   This is likely due to blocking IL-31, IL-4 and IL-13. Overall the cream was well tolerated and did not demonstrate any additional safety concerns in the treatment arms versus vehicle. Ruxolitinib seems to be a promising new and safe alternative for the management of mild to moderate eczema.  This study supports the possible addition of ruxolitinib cream to other treatments available for atopic dermatitis.  More studies will need to be done in the future to confirm these studies.

 

Filed Under: atopic dermatitis, biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page